Furthermore, in gastric cancer, CCL5 levels correlate with tumor progression and prognosis, whereas in breast cancer, CCL5 produced by breast cancer cells increases the production of matrix metalloproteinase by T cells and/or monocytes. This evidence concerns the gene CCL5 and gastric cancer.